Pereda 2003.

Methods	RCT Study aim clearly defined: yes Blinded assessor of primary outcome: no Double blind study: yes Participants comparable at baseline for age: yes Sex: yes Duration of complaint: yes Inclusion and exclusion criteria specified: yes Interventions well described: yes Assessment of compliance: no Intention to treat analysis: no A Priori sample size calculation: not stated Fungi identified: yes Distribution of species between groups: yes Adverse events reported: yes Number of drop outs stated: ten
Participants	Total evaluable sample size:264 Treatment setting: 11 Dermatology outpatient clinics in Spain Inclusion criteria: + ve KOH and culture systemic antimycotic within four weeks of trial entry, topical antifungals within seven days. Concurrent therapy with steroids or other antifungal agent.
Interventions	a. Bifonazole 1% powder b. Flutrimazole 1% powder Both applied 2 X daily for 4 weeks.
Outcomes	Primary outcome:Clinical cure = total signs and symptoms score of < 2. Global cure clinical cure plus negative microscopy
Notes	Adverse events;non serious. Dishydrotic eczema by one in bifonazole group. Itching by one in bifonazole group and one in fluconazole group.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	A ‐ Adequate